Books and Book Chapters

    Xenobiotic Metabolism Activation as a Biomarker of Cigarette Smoke Exposure Response

    Iskandar, A. R.

    Date published
    Sep 10, 2015
    DOI
    10.1007/978-1-4939-2778-4_12
    ISBN
    978-1-4939-2778-4
    Published in
    Computational Systems Toxicology
    Editors
    Hoeng, J.; Peitsch, M. C.
    Link to publication
    Topic
    Summary

    The recent advances in “omics” technologies have generated various in silico approaches for toxicity assessment. In silico-based toxicity predictions can overcome certain major drawbacks of laboratory experiments, including the limitation of conducting experiments in a chemical-by-chemical basis that can be expensive. This chapter discusses some recent applications of in silico approaches utilizing xenobiotic metabolism that can be used to assess the impact of cigarette smoke (CS). We first outline recent studies using quantum mechanics/molecular modeling and quantitative structure–activity relationships that focus on smoking-relevant cytochrome P450 (CYP) enzymes. Subsequently, we describe several network-based approaches for toxicity assessment and relevant use cases leveraging a xenobiotic metabolism network model for a quantitative assessment of CS impact.

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.